NO315200B1 - 2-[amino-6-(cyklopropylamino)-9H-purin-9-yl]-2-cyklopenten-1- metanol-succinat, anvendelse og fremstilling derav og farmasöytisk formuleringinneholdende dette - Google Patents
2-[amino-6-(cyklopropylamino)-9H-purin-9-yl]-2-cyklopenten-1- metanol-succinat, anvendelse og fremstilling derav og farmasöytisk formuleringinneholdende dette Download PDFInfo
- Publication number
- NO315200B1 NO315200B1 NO19970847A NO970847A NO315200B1 NO 315200 B1 NO315200 B1 NO 315200B1 NO 19970847 A NO19970847 A NO 19970847A NO 970847 A NO970847 A NO 970847A NO 315200 B1 NO315200 B1 NO 315200B1
- Authority
- NO
- Norway
- Prior art keywords
- compound according
- amino
- purin
- cyclopropylamino
- methanol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 5
- -1 2- [Amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopentene-1-methanol succinate Chemical compound 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 238000011321 prophylaxis Methods 0.000 claims abstract description 6
- 239000012453 solvate Substances 0.000 claims abstract description 5
- 208000036142 Viral infection Diseases 0.000 claims abstract description 4
- 238000013160 medical therapy Methods 0.000 claims abstract description 4
- 230000009385 viral infection Effects 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000001384 succinic acid Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 241000700721 Hepatitis B virus Species 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 150000003890 succinate salts Chemical class 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 description 30
- 238000009472 formulation Methods 0.000 description 20
- 239000004480 active ingredient Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229940069328 povidone Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010001513 AIDS related complex Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 241000220438 Arachis Species 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007904 elastic gelatin capsule Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229950009795 tucaresol Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Seasonings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9417249A GB9417249D0 (en) | 1994-08-26 | 1994-08-26 | A novel salt |
| PCT/GB1995/002014 WO1996006844A1 (en) | 1994-08-26 | 1995-08-25 | 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol succinate as antiviral agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO970847L NO970847L (no) | 1997-02-25 |
| NO970847D0 NO970847D0 (no) | 1997-02-25 |
| NO315200B1 true NO315200B1 (no) | 2003-07-28 |
Family
ID=10760434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19970847A NO315200B1 (no) | 1994-08-26 | 1997-02-25 | 2-[amino-6-(cyklopropylamino)-9H-purin-9-yl]-2-cyklopenten-1- metanol-succinat, anvendelse og fremstilling derav og farmasöytisk formuleringinneholdende dette |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0777669B1 (hu) |
| JP (1) | JPH10505593A (hu) |
| KR (1) | KR100376240B1 (hu) |
| CN (1) | CN1051550C (hu) |
| AT (1) | ATE220067T1 (hu) |
| AU (1) | AU702618B2 (hu) |
| BR (1) | BR9508629A (hu) |
| CA (1) | CA2198010C (hu) |
| DE (1) | DE69527294T2 (hu) |
| DK (1) | DK0777669T3 (hu) |
| ES (1) | ES2179110T3 (hu) |
| FI (1) | FI120403B (hu) |
| GB (1) | GB9417249D0 (hu) |
| HU (1) | HU221302B1 (hu) |
| IL (1) | IL115074A (hu) |
| MX (1) | MX9701273A (hu) |
| NO (1) | NO315200B1 (hu) |
| NZ (1) | NZ291862A (hu) |
| PT (1) | PT777669E (hu) |
| RU (1) | RU2145324C1 (hu) |
| SI (1) | SI0777669T1 (hu) |
| WO (1) | WO1996006844A1 (hu) |
| ZA (1) | ZA957166B (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| GB9709945D0 (en) | 1997-05-17 | 1997-07-09 | Glaxo Group Ltd | A novel salt |
| AU7912398A (en) * | 1997-05-17 | 1998-12-11 | Glaxo Group Limited | Antiviral combinations containing the carbocyclic nucleoside 1592u89 |
| NZ500868A (en) * | 1997-05-17 | 2001-08-31 | Glaxo Group Ltd | Antiviral combinations comprising 1592U89 and HIV protease inhibitors |
| SK284595B6 (sk) * | 1997-11-27 | 2005-07-01 | Lonza Ag | Spôsob výroby (1S,4R)-4-(2-amino-6-chlór-9H-purín-9-yl)-2- cyklopentén-1-metanolu alebo jeho solí |
| GB9802472D0 (en) * | 1998-02-06 | 1998-04-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB9903091D0 (en) * | 1999-02-12 | 1999-03-31 | Glaxo Group Ltd | Therapeutic nucleoside compound |
| AU2002355739A1 (en) | 2001-07-30 | 2003-02-17 | University Of Southern California | Preparation and use of alpha-keto phosphonates |
| JP4542550B2 (ja) * | 2003-10-27 | 2010-09-15 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｃｒ−２アンタゴニスト塩 |
| EP2305680A3 (en) * | 2009-09-30 | 2011-05-18 | Aurobindo Pharma Limited | Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol |
| EP2697238B1 (en) | 2011-04-08 | 2019-03-20 | Laurus Labs Limited | Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof |
| US9457028B2 (en) | 2013-02-27 | 2016-10-04 | Kyoto University | Pharmaceutical composition for use in prevention or treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3025492A1 (de) * | 1980-07-04 | 1982-02-04 | Siemens AG, 1000 Berlin und 8000 München | Filterelement fuer die optische nachrichtentechnik |
| GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| IL104283A (en) * | 1992-12-30 | 1996-12-05 | Agis Ind 1983 Ltd | Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate |
-
1994
- 1994-08-26 GB GB9417249A patent/GB9417249D0/en active Pending
-
1995
- 1995-08-25 BR BR9508629A patent/BR9508629A/pt not_active Application Discontinuation
- 1995-08-25 ES ES95929954T patent/ES2179110T3/es not_active Expired - Lifetime
- 1995-08-25 DE DE69527294T patent/DE69527294T2/de not_active Expired - Lifetime
- 1995-08-25 WO PCT/GB1995/002014 patent/WO1996006844A1/en active IP Right Grant
- 1995-08-25 KR KR1019970701213A patent/KR100376240B1/ko not_active IP Right Cessation
- 1995-08-25 RU RU97104483A patent/RU2145324C1/ru active
- 1995-08-25 IL IL11507495A patent/IL115074A/en not_active IP Right Cessation
- 1995-08-25 AU AU33509/95A patent/AU702618B2/en not_active Expired
- 1995-08-25 PT PT95929954T patent/PT777669E/pt unknown
- 1995-08-25 NZ NZ291862A patent/NZ291862A/en not_active IP Right Cessation
- 1995-08-25 HU HU9701756A patent/HU221302B1/hu unknown
- 1995-08-25 JP JP8508550A patent/JPH10505593A/ja active Pending
- 1995-08-25 EP EP95929954A patent/EP0777669B1/en not_active Expired - Lifetime
- 1995-08-25 CN CN95194789A patent/CN1051550C/zh not_active Expired - Lifetime
- 1995-08-25 AT AT95929954T patent/ATE220067T1/de active
- 1995-08-25 MX MX9701273A patent/MX9701273A/es active IP Right Grant
- 1995-08-25 SI SI9530614T patent/SI0777669T1/xx unknown
- 1995-08-25 CA CA002198010A patent/CA2198010C/en not_active Expired - Lifetime
- 1995-08-25 DK DK95929954T patent/DK0777669T3/da active
- 1995-08-25 ZA ZA9507166A patent/ZA957166B/xx unknown
-
1997
- 1997-02-25 NO NO19970847A patent/NO315200B1/no not_active IP Right Cessation
- 1997-02-25 FI FI970786A patent/FI120403B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA957166B (en) | 1997-02-25 |
| IL115074A0 (en) | 1995-12-08 |
| SI0777669T1 (en) | 2002-12-31 |
| GB9417249D0 (en) | 1994-10-19 |
| IL115074A (en) | 1998-10-30 |
| PT777669E (pt) | 2002-11-29 |
| CA2198010C (en) | 2006-05-02 |
| CA2198010A1 (en) | 1996-03-07 |
| DE69527294D1 (en) | 2002-08-08 |
| RU2145324C1 (ru) | 2000-02-10 |
| BR9508629A (pt) | 1997-11-25 |
| DK0777669T3 (da) | 2002-10-28 |
| AU702618B2 (en) | 1999-02-25 |
| DE69527294T2 (de) | 2003-02-13 |
| CN1051550C (zh) | 2000-04-19 |
| HU221302B1 (en) | 2002-09-28 |
| NO970847L (no) | 1997-02-25 |
| CN1156456A (zh) | 1997-08-06 |
| EP0777669A1 (en) | 1997-06-11 |
| AU3350995A (en) | 1996-03-22 |
| NO970847D0 (no) | 1997-02-25 |
| FI970786A0 (fi) | 1997-02-25 |
| ATE220067T1 (de) | 2002-07-15 |
| FI120403B (fi) | 2009-10-15 |
| JPH10505593A (ja) | 1998-06-02 |
| KR970705563A (ko) | 1997-10-09 |
| FI970786A (fi) | 1997-02-25 |
| NZ291862A (en) | 1998-02-26 |
| ES2179110T3 (es) | 2003-01-16 |
| HUT77222A (hu) | 1998-03-02 |
| WO1996006844A1 (en) | 1996-03-07 |
| EP0777669B1 (en) | 2002-07-03 |
| MX9701273A (es) | 1997-05-31 |
| KR100376240B1 (ko) | 2003-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2972014C (en) | Fused pyrimidine compounds for the treatment of hiv | |
| CA2972017C (en) | Isoquinoline compounds for the treatment of hiv | |
| KR100542536B1 (ko) | 지도부딘,1592u89및3tc또는ftc의상승작용성복합제제 | |
| CS342591A3 (en) | Pharmaceuticals comprising 1-(beta-d-arabinofuranosyl)-5-propinyluracil | |
| NO315200B1 (no) | 2-[amino-6-(cyklopropylamino)-9H-purin-9-yl]-2-cyklopenten-1- metanol-succinat, anvendelse og fremstilling derav og farmasöytisk formuleringinneholdende dette | |
| US6294540B1 (en) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | |
| CN1036398C (zh) | 治疗用核苷 | |
| CA2044125A1 (en) | Anti-hbv pyrimidine nucleoside | |
| EP0979082A1 (en) | Antiviral combinations containing the carbocyclic nucleoside 1592u89 | |
| AU769660B2 (en) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | |
| TW202214593A (zh) | 感冒劑及抗病毒劑 | |
| MXPA99010373A (en) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | |
| CZ406899A3 (cs) | Hemisulfát (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanolu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |